The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Affiliation
Comparative Outcomes Group, Bristol UK
Country
United Kingdom
1. Current Status, Position
Dr Paul Cornes (BM BCH MA MRCP FRCR) is an Oncologist from Bristol, UK.
2. Education
Dr Paul Cornes trained in Medicine at Oxford University and in Oncology at the Royal Marsden Hospital, London, UK before becoming a Consultant Oncologist in Bristol, UK.
3. Research Area
Dr Paul Cornes is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment. He was part of the team that developed and presented evidence to the Oncology Advisory drugs Committee of the FDA for the first successfully approved US biosimilar. He has been in the British Medical Journal’s “Round Table” group on Biosimilars and has been on the panel for the EU Commission biosimilars meeting in Brussels.
4. Conflict of interest: Dr Paul Cornes received honoraria from the following companies for speaking at meetings in 2016:
- Amgen
- Generic and Biosimilar Medecines Association – Australia
- Merck Serono
- Napp
- Sandoz